Bipolar Disorder: An Update

@article{ElMallakh2010BipolarDA,
  title={Bipolar Disorder: An Update},
  author={Rif S El-Mallakh and Ahmed Z. Elmaadawi and Muruga Loganathan and Kavita Lohano and Yonglin Gao},
  journal={Postgraduate Medicine},
  year={2010},
  volume={122},
  pages={24 - 31}
}
Abstract There has been a recent increase in the number of clinical trials and treatment options for bipolar disorder. This research has resulted in new treatment options. Most second-generation antipsychotics have demonstrated efficacy in the treatment of mania, both in monotherapy and as adjuncts to mood stabilizers. For bipolar depression, nearly all randomized, placebo-controlled studies have demonstrated that antidepressants do not provide any additional benefit to ongoing mood stabilizers… Expand
Risk and efficacy in cognitive functions in Bipolar Disorder II with atypical antipsychotic augmentation.
TLDR
It is shown that atypical antipsychotics cause an improvement in symptoms in BD, and particularly BD II, and some SGAs, such as quetiapine and asenapine, seem to demonstrate a not statistically significant mild improvement in cognition. Expand
Treatment-induced manic switch in the course of unipolar depression can predict bipolarity: cluster analysis based evidence.
TLDR
The findings of this study confirm that treatment-induced mania is a clinical phenomenon that belongs within the bipolar spectrum rather than a coincidental treatment complication, and that it should be placed under "bipolar disorders" in future classification systems. Expand
Review of animal models of bipolar disorder that alter ion regulation
TLDR
Alpha3 KOs appear to be the best characterized animal model for bipolar disorder currently available and are thus the most promising models available, while other models are important for demonstrating mechanisms in important pathophysiologic aspect of bipolar disorder. Expand
Associations of the serotonin transporter promoter polymorphism (5-HTTLPR) with bipolar disorder and treatment response: A systematic review and meta-analysis
TLDR
The present study supported the presence of a marginal but detectable effect of the 5‐HTTLPR on susceptibility to BPD and identified it as a useful predictor for anti‐depressive remission but not for anti-depressive or anti‐manic response. Expand
A 2-year follow-up study of discharged psychiatric patients with bipolar disorder
TLDR
The results of the follow-up indicated that the situation of patients with bipolar disorder after discharge is not optimistic, because of high recurrence rates, high non-compliance rates and low recovery rates. Expand
Research Domain Criteria versus DSM V: How does this debate affect attempts to model corticostriatal dysfunction in animals?
TLDR
The suitability of RDoC vs. DSM from the view of modeling mental illness in animals is addressed, which will focus on models of conditions associated with frontostriatal dysfunction. Expand
Genome-wide supported risk variant for bipolar disorder alters anatomical connectivity in the human brain
TLDR
The findings show that ANK3 rs10994336 or a variant in linkage-disequilibrium is functional in the human brain and also influences behavioral phenotypes related to bipolar disorder. Expand
Cariprazine delays ouabain-evoked epileptiform spikes and loss of activity in rat hippocampal slices
TLDR
It is suggested that cariprazine may have therapeutic potential for treatment of bipolar disorder because it delays the onset of ouabain-induced epileptiform bursts and the loss of spiking activity similarly to that previously demonstrated with the mood stabilizer lithium. Expand
Molecular Imaging of Depressive Disorders
This chapter summarizes findings of a large number of molecular imaging studies in the field of unipolar and bipolar depression (BD).
Review Article 14-3-3 proteins in neurological disorders
TLDR
Previous and more recent research is reviewed that has helped to understand the roles of 14-3-3 proteins in both neurodegenerative and neuropsychiatric diseases. Expand
...
1
2
...

References

SHOWING 1-10 OF 72 REFERENCES
Antipsychotic medications in the treatment of bipolar disorder.
TLDR
This paper will critically review available randomized clinical trials utilizing antipsychotic agents in bipolar disorder and suggest that both first and second generation agents appear to have a beneficial effect. Expand
Bipolar II disorder: current and future treatment options.
TLDR
The most efficacious agents are likely those with bimodal stabilizing properties, such as lithium, carbamazepine, and quetiapine, which recently became the first agent to be indicated by the FDA for monotherapeutic use in the treatment of bipolar depression, including BPII depression. Expand
Mood state at study entry as predictor of the polarity of relapse in bipolar disorder
TLDR
It is concluded that putative mood stabilizers must be tested in recently manic and recently depressed patients to determine their spectrum of prophylactic efficacy. Expand
Effectiveness of adjunctive antidepressant treatment for bipolar depression.
TLDR
The use of adjunctive, standard antidepressant medication, as compared with the use of mood stabilizers, was not associated with increased efficacy or with increased risk of treatment-emergent affective switch. Expand
A double-blind trial of bupropion versus desipramine for bipolar depression.
TLDR
A prospective double-blind trial to assess efficacy and rate of treatment-emergent mood elevation in depressed bipolar patients when bupropion or desipramine was added to an ongoing therapeutic regimen of lithium or an anticonvulsant suggests that bupropions is less likely to induce mood elevation than desipramsine. Expand
Aripiprazole Monotherapy in Nonpsychotic Bipolar I Depression: Results of 2 Randomized, Placebo-Controlled Studies
TLDR
Aripiprazole monotherapy-as dosed in this study design-was not significantly more effective than placebo in the treatment of bipolar depression at end point (Week 8), and despite early statistical separation on the Clinical Global Impressions Bipolar Version Severity of Illness-Depression score (key secondary end point), aripIPrazole was not superior to placebo at endpoint. Expand
Antidepressant-associated chronic irritable dysphoria (acid) in bipolar disorder: a case series.
TLDR
A case series is presented in which six type I bipolar subjects receiving antidepressants continuously for several years developed chronic irritable dysphoria, which became chronic and resulted in dysfunction. Expand
A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network.
TLDR
Despite intensive naturalistic treatment, the 258 outpatients with bipolar illness followed prospectively for 1 year showed three times as many days depressed as days manic, re-emphasizing the considerable depressive morbidity that remains in bipolar disorder despite the number of treatment options available. Expand
A critical update on psychological interventions for bipolar disorders
TLDR
The effectiveness of psychosocial approaches to bipolar illness is critically examined by reviewing the literature, which has been substantially enriched during the past 5 years and further support the fact that psychoeducation and cognitivebehavioral therapy are effective in bipolar disorder, especially the early stages. Expand
Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127).
TLDR
In patients stabilized on quetiapine plus lithium or divalproex, continued treatment was associated with a significant risk reduction in the time to recurrence of any mood event compared with placebo and lithium ordivalproEx. Expand
...
1
2
3
4
5
...